iZafe Engages Mangold Fondkommission as Liquidity Provider
STOCKHOLM, SE / ACCESSWIRE / November 29, 2021 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe") has entered into an agreement with Mangold Fondkommission AB (Mangold) as liquidity provider for the iZafe share on Nasdaq First North Growth Market. The purpose of the liquidity provider is to improve the liquidity of the share and decrease the spread between the ask and bid price. Mangold's assignment commences on November 30, 2021.
In its assignment as liquidity provider, Mangold will facilitate trade in the iZafe share by continuously maintaining both ask and bid orders in the order book. The purpose is to ensure a more accurate share price, which leads to a more accurate company valuation and improves the trading volume of the share.
Carl-Fredrik Bothén, Chief Marketing Officer
Phone number: +46 73-064 48 67
Anders Segerström, Chief Executive Officer
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm
iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.
The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: email@example.com. Further information is available at www.izafe.se/investor-relations/.
SOURCE: iZafe Group
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
XPhyto Therapeutics Corp. 24.1.2022 09:06:46 CET | Press release
XPhyto Provides Update on Integration of 3a-diagnostics GmbH
Cyberlux Corporation21.1.2022 17:32:37 CET | Press release
Cyberlux Corporation Announces Mr. Chris Damvakaris as Chief Revenue Officer to Lead the Revenue Growth Plans and Strategic Partnerships for the Advanced Digital Technology Company
Episode Six18.1.2022 15:04:37 CET | Press release
Third Anniversary of Episode Six and HSBC's Partnership Shows the Power of Banks and Fintechs Working Together
XPhyto Therapeutics Corp. 17.1.2022 09:06:46 CET | Press release
XPhyto Announces Head of Sales, Europe
Loop Industries, Inc.16.1.2022 22:01:39 CET | Press release
Loop Industries Announces Selection of Port-Jérôme, in Normandy, France, as Site for First European Infinite Loop Manufacturing Facility
XPhyto Therapeutics Corp13.1.2022 09:07:06 CET | Press release
XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia
XPhyto Therapeutics Corp. 10.1.2022 09:06:52 CET | Press release
XPhyto Announces New Director of Business Development and Head of Diagnostic Research
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom